- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01478373
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
26. april 2016 opdateret af: Novartis Pharmaceuticals
DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
The purpose of this study is to evaluate the efficacy and safety of Dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to Imatinib
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
39
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
HUS, Finland, FIN-00029
- Novartis Investigative Site
-
-
-
-
-
Bordeaux, Frankrig, 33076
- Novartis Investigative Site
-
Lille Cedex, Frankrig, 59020
- Novartis Investigative Site
-
Lyon Cedex, Frankrig, 69373
- Novartis Investigative Site
-
Reims, Frankrig, 51092
- Novartis Investigative Site
-
Villejuif Cedex, Frankrig, 94805
- Novartis Investigative Site
-
-
-
-
MI
-
Milano, MI, Italien, 20133
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italien, 00168
- Novartis Investigative Site
-
-
TO
-
Candiolo, TO, Italien, 10060
- Novartis Investigative Site
-
Torino, TO, Italien, 10153
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spanien, 08041
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spanien, 08035
- Novartis Investigative Site
-
Hospitalet de LLobregat, Catalunya, Spanien, 08907
- Novartis Investigative Site
-
-
Islas Baleares
-
Palma De Mallorca, Islas Baleares, Spanien, 07120
- Novartis Investigative Site
-
-
-
-
-
Essen, Tyskland, 45147
- Novartis Investigative Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Histologically confirmed GIST of any anatomical location, which is 1) unresectable and/ or metastatic with documented disease progression while on therapy with imatinib or 2) surgically removed localized GIST, recurrent on adjuvant imatinib or recurrent within the first 3 months after discontinuation of adjuvant imatinib or 3) patients with unresectable and/or metastatic GIST intolerant to imatinib
- Positive immunohistochemical staining for c-KIT (CD117); or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation of KIT or PDGFRA gene
- Documented disease progression according to RECIST (version 1.1) on prior therapy with imatinib at a dose of at least 400mg/day or patients with unresectable and/or metastatic GIST who are intolerant to imatinib
- At least one measurable GIST lesion according to RECIST (version 1.1).
- Adequate bone marrow, liver and renal function
Exclusion Criteria:
- Patients who have received any other tyrosine-kinase inhibitor but imatinib for GIST
- Patients who received cytotoxic drugs ≤ 4 weeks prior to starting Dovitinib (TKI258)
- Patients who are treated or planned to be treated concomitantly with other cytotoxic or antineoplastic treatments, such as chemotherapy, immunotherapy, biological response modifiers, or radiotherapy
- Patients with another primary malignancy within 3 years prior to starting the study drug
- Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) ≤ 4 weeks prior to starting Dovitinib (TKI258) or who have not recovered from the adverse effects of such therapy
- Patients with a history of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) within the past 6 months
- Patients with impaired cardiac function or clinically significant cardiac diseases
- Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Dovitinib
- Patients with prior complete gastrectomy
- Patients with brain metastasis or history of brain metastasis
- Patients who are currently receiving anticoagulation treatment with therapeutic doses of warfarin or equivalent anticoagulant
- Pregnant or breast-feeding women
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Dovitinib (TKI258)
Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
|
Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease
Tidsramme: 12 Weeks
|
DCR is defined as the proportion of patients with a best overall response of Complete Responses (CR), Partial Response (PR) and Stable Disease (SD) at 12 weeks according to RECIST (version 1.1).
Complete Response (CR): Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
12 Weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression-free Survival (PFS) of Patients Treated With Dovitinib
Tidsramme: 9 months
|
The PFS duration: time from entry into the study to the date of the first documented progression (assessed using conventional RECIST (version 1.1) or death due to any cause.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
9 months
|
Time to Treatment Failure (TTF)of Patients Treated With Dovitinib
Tidsramme: 9 months
|
TTF: the date of entry into the study to the earliest date of the first objective tumor progression, date of death due to any cause, or date of discontinuation due to reasons other than 'Protocol deviation' or 'Administrative problems'.
|
9 months
|
Duration of Response or Stable Disease (SD)
Tidsramme: 9 months
|
Duration of response or SD: time from date of entry into study to earliest date of first objective tumor progression or death.
DCR is defined as proportion of patients with best overall response of CR, PR and SD at 12 weeks according to RECIST (version 1.1).
CR: Disappearance of all non-nodal target lesions.
Any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1; PR: At least a 30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
PD: At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
9 months
|
Time to Tumor Progression (TTP)of Patients Treated With Dovitinib
Tidsramme: 9 months
|
TTP: time from the date of entry into the study to first documentation of tumor progression or death due to the underlying cancer.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
9 months
|
Overall Response Rate (ORR) of Patients Treated With Dovitinib
Tidsramme: Baseline, 12 weeks
|
Outcome Measure Description: ORR: proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST (version 1.1).
Complete Response (CR): Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
Baseline, 12 weeks
|
Overall Survival (OS) of Patients Treated With Dovitinib
Tidsramme: 21 months (9 months of estimated treatment plus 12 months of survival follow up)
|
Outcome Measure Description: OS: time from the date of entry into the study to the date of death due to any cause.
A patient who has not died by the date of the analysis cut-off would have the OS censored at the time of the last contact before the cut-off date.
|
21 months (9 months of estimated treatment plus 12 months of survival follow up)
|
DCR (CR+PR+SD) at the End of Treatment
Tidsramme: Up to 9 months of estimated treatment
|
DCR is defined as the proportion of patients with a best overall response of CR, PR and SD at the end of dovitinib treatment according to RECIST (version 1.1).
Complete Response (CR): Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
Up to 9 months of estimated treatment
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. januar 2012
Primær færdiggørelse (Faktiske)
1. juli 2014
Studieafslutning (Faktiske)
1. juli 2014
Datoer for studieregistrering
Først indsendt
16. november 2011
Først indsendt, der opfyldte QC-kriterier
21. november 2011
Først opslået (Skøn)
23. november 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
27. april 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. april 2016
Sidst verificeret
1. april 2016
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CTKI258AIC02
- 2011-001725-24 (EudraCT nummer)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Gastrointestinale stromale tumorer
-
Hospital Universitario Virgen de la ArrixacaIkke rekrutterer endnuLeversygdomme | Levertransplantation | Neoplasmer i leveren | Gastrointestinale stromale tumorer | Metastase | Levermetastaser | Levertransplantation; Komplikationer | Leverkræft | Levertransplantationslidelse | Leverkarcinom | GIST, ondartet | GIST | Metastaser | Metastatisk leverkræft | Gastrointestinal stromal tumor i... og andre forholdSpanien
-
Centre Leon BerardRekrutteringMetastatisk gastrointestinal stromal tumor | Ikke-operabel gastrointestinal stromal tumor (GIST) | Lokalt avanceret gastrointestinal stromal tumor (GIST)Frankrig
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk gastrointestinal stromal tumor | Metastatisk sarkom | Lokalt avanceret sarkom | Lokalt avanceret gastrointestinal stromal tumor | Fase III gastrisk og omental gastrointestinal stromal tumor AJCC v8 | Stadie III tyndtarm, esophageal, kolorektal, mesenterisk og peritoneal gastrointestinal... og andre forholdForenede Stater
-
Centre Leon BerardRekrutteringC-KIT mutation | Metastatisk gastrointestinal stromal tumor (GIST) | Avanceret gastrointestinal stromal tumor (GIST)Frankrig
-
ARCAGY/ GINECO GROUPRoche Pharma AGAfsluttet
-
National Cancer Institute (NCI)RekrutteringMavekræft | Mave-neoplasma | Gastrointestinal stromal tumor (GIST) | Gastrointestinal stromal sarkom | Gastrointestinal stromal neoplasmaForenede Stater
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.RekrutteringSolid tumor, voksen | Gastrointestinal stromal tumor (GIST)Kina
-
Assaf-Harofeh Medical CenterUkendtBlødt vævssarkom | Osteosarkom | Kondrosarkom | Knoglesarkom | Desmoplastisk lille rundcellet tumor | Gastrointestinal stromal sarkom | Ewings tumor metastatisk | Ewings tilbagevendende tumor
-
Australasian Gastro-Intestinal Trials GroupEuropean Organisation for Research and Treatment of Cancer - EORTC; Scandinavian...Aktiv, ikke rekrutterendeGastrointestinal stromal tumorSingapore, Norge, Finland, Australien, Sverige, Frankrig, Det Forenede Kongerige, Spanien, Holland, Slovakiet
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbAfsluttetGastrointestinal stromal tumorForenede Stater
Kliniske forsøg med Dovitinib (TKI258)
-
Novartis PharmaceuticalsAfsluttetMetastatisk brystkræftForenede Stater, Canada, Finland, Frankrig, Italien, Spanien, Taiwan, Det Forenede Kongerige
-
M.D. Anderson Cancer CenterNovartisAfsluttet
-
Novartis PharmaceuticalsAfsluttetNeoplasmer | Kræft | TumorerForenede Stater
-
Korean Cancer Study GroupAfsluttetHormonrefraktær prostatakræftKorea, Republikken
-
Novartis PharmaceuticalsAfsluttetTumor Pathway-aktiveringer hæmmet af DovitinibForenede Stater
-
Novartis PharmaceuticalsAfsluttetEndometriecancer | VEGF | Solide tumorer og avanceret endometriecancer | Anden linjes behandlingItalien, Det Forenede Kongerige, Spanien, Brasilien, Forenede Stater, Korea, Republikken, New Zealand
-
Auckland District Health BoardNovartis; University of Auckland, New Zealand; IGENZ, Ltd., AucklandUkendtKlarcellet nyrecellekarcinomNew Zealand
-
Novartis PharmaceuticalsAfsluttetAvancerede solide tumorer | Undtagen brystkræftForenede Stater
-
Novartis PharmaceuticalsAfsluttetKræft | Neoplasma | TumorerForenede Stater
-
Novartis PharmaceuticalsAfsluttet